{"id":51127,"date":"2025-12-17T19:12:39","date_gmt":"2025-12-17T11:12:39","guid":{"rendered":"https:\/\/flcube.com\/?p=51127"},"modified":"2025-12-17T19:12:41","modified_gmt":"2025-12-17T11:12:41","slug":"haisco-wins-nmpa-clinical-approval-for-four-category-1-drugs-advancing-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51127","title":{"rendered":"Haisco Wins NMPA Clinical Approval for Four Category 1 Drugs, Advancing Pipeline"},"content":{"rendered":"\n<p><strong>Haisco Pharmaceutical Group Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/002653:SHE\">SHE: 002653<\/a>) announced that China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> granted clinical approval for four <strong>Category 1 chemical drugs<\/strong>: <strong>HSK45019<\/strong> (IBD), <strong>HSK50042<\/strong> (respiratory disease), <strong>HSK55718<\/strong> (acute pain), and <strong>HSK36357<\/strong> (muscular dystrophy), advancing its innovative pipeline across multiple therapeutic areas.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-approvals-overview\">Clinical Trial Approvals Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Formulation<\/th><th>Mechanism<\/th><th>Indication<\/th><th>Innovation Status<\/th><\/tr><\/thead><tbody><tr><td><strong>HSK45019<\/strong><\/td><td>Tablets<\/td><td>Small-molecule inhibitor<\/td><td>Inflammatory bowel disease (IBD)<\/td><td>Category 1, proprietary IP<\/td><\/tr><tr><td><strong>HSK50042<\/strong><\/td><td>Tablets<\/td><td>Highly selective small-molecule inhibitor<\/td><td>Respiratory diseases<\/td><td>Category 1, oral administration<\/td><\/tr><tr><td><strong>HSK55718<\/strong><\/td><td>Injection<\/td><td>Small-molecule analgesic<\/td><td>Acute pain<\/td><td>Category 1, non-addictive profile<\/td><\/tr><tr><td><strong>HSK36357<\/strong><\/td><td>Capsules<\/td><td>Novel small-molecule drug<\/td><td>Muscular dystrophy (BMD\/DMD)<\/td><td>Category 1, novel mechanism<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-individual-drug-profiles\">Individual Drug Profiles<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-hsk45019-ibd-treatment\">HSK45019 \u2013 IBD Treatment<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Proprietary small-molecule inhibitor<\/li>\n\n\n\n<li><strong>Potential:<\/strong> Novel therapeutic approach for IBD patients<\/li>\n\n\n\n<li><strong>Market:<\/strong> China IBD market \u00a58\u201110\u202fbillion (\u2248\u202fUS$1.1\u20111.4\u202fB) with 10% CAGR<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-hsk50042-respiratory-disease\">HSK50042 \u2013 Respiratory Disease<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Highly selective oral small-molecule inhibitor<\/li>\n\n\n\n<li><strong>Preclinical Data:<\/strong> Improved lung disease pathology in model mice at low doses<\/li>\n\n\n\n<li><strong>Safety:<\/strong> Good tolerability and wide safety margin<\/li>\n\n\n\n<li><strong>Market:<\/strong> China respiratory drug market \u00a525\u202fbillion (\u2248\u202fUS$3.5\u202fB)<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-hsk55718-acute-pain-management\">HSK55718 \u2013 Acute Pain Management<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Independently developed small-molecule analgesic<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> No significant cardiovascular, CNS, or respiratory effects at supratherapeutic doses<\/li>\n\n\n\n<li><strong>Advantage:<\/strong> Effective analgesia with minimized adverse reactions and no addiction risk<\/li>\n\n\n\n<li><strong>Market:<\/strong> Global acute pain market $12\u202fbillion; China segment \u00a53\u202fbillion<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-hsk36357-muscular-dystrophy\">HSK36357 \u2013 Muscular Dystrophy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Novel small-molecule drug enhancing skeletal muscle contractility<\/li>\n\n\n\n<li><strong>Preclinical Efficacy:<\/strong> Significant analgesic effect, improved muscle fatigue recovery in DMD models<\/li>\n\n\n\n<li><strong>Safety:<\/strong> Good tolerability in animal studies<\/li>\n\n\n\n<li><strong>Market:<\/strong> Global muscular dystrophy market $1.5\u202fbillion; China DMD\/BMD population ~70,000<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For Haisco:<\/strong> <strong>Four simultaneous Category 1 approvals<\/strong> validate proprietary R&amp;D platform and diversified therapeutic strategy; strengthens position in <strong>innovation\u2011driven drug development<\/strong> with potential for <strong>global out\u2011licensing<\/strong>.<\/li>\n\n\n\n<li><strong>For Pipeline:<\/strong> Addresses <strong>high\u2011unmet\u2011need areas<\/strong> across immunology, respiratory, pain management, and rare diseases; reduces reliance on single\u2011asset risk.<\/li>\n\n\n\n<li><strong>For Market:<\/strong> Demonstrates China\u2019s accelerating <strong>Category 1 drug innovation<\/strong>; competitive advantages include <strong>proprietary IP<\/strong>, <strong>novel mechanisms<\/strong>, and <strong>improved safety profiles<\/strong>.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical trial timelines, market size estimates, and competitive positioning. Actual results may differ due to regulatory feedback, clinical risks, or competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/\u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u83b7\u5f97\u521b\u65b0\u836f\u300a\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u300b\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u83b7\u5f97\u521b\u65b0\u836f\u300a\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u300b\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-c1e96024-b031-4844-babb-4ec4f7d79905\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/\u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u83b7\u5f97\u521b\u65b0\u836f\u300a\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u300b\u7684\u516c\u544a.pdf\">\u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u83b7\u5f97\u521b\u65b0\u836f\u300a\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u300b\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/\u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u83b7\u5f97\u521b\u65b0\u836f\u300a\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u300b\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c1e96024-b031-4844-babb-4ec4f7d79905\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that China\u2019s National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":51132,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,139,929],"class_list":["post-51127","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-haisco-pharmaceutical","tag-she-002653"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Haisco Wins NMPA Clinical Approval for Four Category 1 Drugs, Advancing Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that China\u2019s National Medical Products Administration (NMPA) granted clinical approval for four Category 1 chemical drugs: HSK45019 (IBD), HSK50042 (respiratory disease), HSK55718 (acute pain), and HSK36357 (muscular dystrophy), advancing its innovative pipeline across multiple therapeutic areas.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=51127\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Haisco Wins NMPA Clinical Approval for Four Category 1 Drugs, Advancing Pipeline\" \/>\n<meta property=\"og:description\" content=\"Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that China\u2019s National Medical Products Administration (NMPA) granted clinical approval for four Category 1 chemical drugs: HSK45019 (IBD), HSK50042 (respiratory disease), HSK55718 (acute pain), and HSK36357 (muscular dystrophy), advancing its innovative pipeline across multiple therapeutic areas.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=51127\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-17T11:12:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-17T11:12:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1701.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51127#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51127\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Haisco Wins NMPA Clinical Approval for Four Category 1 Drugs, Advancing Pipeline\",\"datePublished\":\"2025-12-17T11:12:39+00:00\",\"dateModified\":\"2025-12-17T11:12:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51127\"},\"wordCount\":358,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51127#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1701.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Haisco Pharmaceutical\",\"SHE: 002653\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51127#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51127\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=51127\",\"name\":\"Haisco Wins NMPA Clinical Approval for Four Category 1 Drugs, Advancing Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51127#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51127#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1701.webp\",\"datePublished\":\"2025-12-17T11:12:39+00:00\",\"dateModified\":\"2025-12-17T11:12:41+00:00\",\"description\":\"Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that China\u2019s National Medical Products Administration (NMPA) granted clinical approval for four Category 1 chemical drugs: HSK45019 (IBD), HSK50042 (respiratory disease), HSK55718 (acute pain), and HSK36357 (muscular dystrophy), advancing its innovative pipeline across multiple therapeutic areas.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51127#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51127\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51127#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1701.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1701.webp\",\"width\":1080,\"height\":608,\"caption\":\"Haisco Wins NMPA Clinical Approval for Four Category 1 Drugs, Advancing Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51127#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Haisco Wins NMPA Clinical Approval for Four Category 1 Drugs, Advancing Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Haisco Wins NMPA Clinical Approval for Four Category 1 Drugs, Advancing Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that China\u2019s National Medical Products Administration (NMPA) granted clinical approval for four Category 1 chemical drugs: HSK45019 (IBD), HSK50042 (respiratory disease), HSK55718 (acute pain), and HSK36357 (muscular dystrophy), advancing its innovative pipeline across multiple therapeutic areas.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=51127","og_locale":"en_US","og_type":"article","og_title":"Haisco Wins NMPA Clinical Approval for Four Category 1 Drugs, Advancing Pipeline","og_description":"Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that China\u2019s National Medical Products Administration (NMPA) granted clinical approval for four Category 1 chemical drugs: HSK45019 (IBD), HSK50042 (respiratory disease), HSK55718 (acute pain), and HSK36357 (muscular dystrophy), advancing its innovative pipeline across multiple therapeutic areas.","og_url":"https:\/\/flcube.com\/?p=51127","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-17T11:12:39+00:00","article_modified_time":"2025-12-17T11:12:41+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1701.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=51127#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=51127"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Haisco Wins NMPA Clinical Approval for Four Category 1 Drugs, Advancing Pipeline","datePublished":"2025-12-17T11:12:39+00:00","dateModified":"2025-12-17T11:12:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=51127"},"wordCount":358,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=51127#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1701.webp","keywords":["Clinical trial approval \/ initiation","Haisco Pharmaceutical","SHE: 002653"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=51127#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=51127","url":"https:\/\/flcube.com\/?p=51127","name":"Haisco Wins NMPA Clinical Approval for Four Category 1 Drugs, Advancing Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=51127#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=51127#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1701.webp","datePublished":"2025-12-17T11:12:39+00:00","dateModified":"2025-12-17T11:12:41+00:00","description":"Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that China\u2019s National Medical Products Administration (NMPA) granted clinical approval for four Category 1 chemical drugs: HSK45019 (IBD), HSK50042 (respiratory disease), HSK55718 (acute pain), and HSK36357 (muscular dystrophy), advancing its innovative pipeline across multiple therapeutic areas.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=51127#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=51127"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=51127#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1701.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1701.webp","width":1080,"height":608,"caption":"Haisco Wins NMPA Clinical Approval for Four Category 1 Drugs, Advancing Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=51127#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Haisco Wins NMPA Clinical Approval for Four Category 1 Drugs, Advancing Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1701.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=51127"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51127\/revisions"}],"predecessor-version":[{"id":51133,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51127\/revisions\/51133"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/51132"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=51127"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=51127"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=51127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}